Minerva Neurosciences, Inc. NERV Balance Sheet

Minerva neurosciences, inc. (NERV)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Jun'14	Dec'13
Assets
Current assets
Cash and cash equivalents
30,036	21,412	37,905	27,844	30,607	50,234	87,296	68,688	45,125	26,051	36,254	50,191	68,894	82,980	91,853	88,670	34,822	14,284	16,836	21,735	52,200	18,545	480	1,818
Marketable securities
7,478	24,441	22,026	41,448	48,556	37,762	10,308	39,798	75,871	102,109	96,675	27,381	16,464	-	-	8,386	9,817	17,920	20,650	13,650	-	-	-	-
Restricted cash
100	100	100	100	100	100	-	-	-	80	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	100	100	100	-	80	80	80	80	80	80	80	80	80	80	40	35	-	-
Prepaid expenses and other current assets
851	1,182	1,376	1,453	1,054	1,921	3,699	3,229	4,243	1,299	1,072	421	791	803	702	278	617	1,196	1,243	308	503	756	33	0
Total current assets
38,466	47,136	61,409	70,846	80,318	90,018	101,404	111,816	125,340	129,540	134,082	78,074	86,230	83,863	92,635	97,415	45,337	33,480	38,810	35,775	52,744	19,337	513	1,819
Marketable securities - noncurrent
-	-	-	-	-	-	-	-	-	5,022	10,355	-	-	-	-	-	-	-	1,407	9,443	-	-	-	-
Equipment, net
11	16	20	24	29	33	37	42	46	50	0	3	6	9	13	17	21	26	30	34	33	43	27	3
Other noncurrent assets
14	14	14	14	14	14	14	14	14	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease right-of-use assets
223	261	299	335	371	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development
15,200	15,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	34,200	19,000
Goodwill
14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	14,869	15,104	7,918
Deferred public offering costs
-	-	-	-	-	-	-	-	-	-	-	232	-	-	-	-	-	-	-	-	-	-	-	-
Deferred public offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,111	433
Total assets
68,785	77,498	110,813	120,291	129,803	139,136	150,526	160,943	174,471	183,698	193,507	127,379	135,306	132,942	141,718	146,502	94,428	82,576	89,318	94,323	101,847	68,450	52,956	29,174
Liabilities and Stockholders’ Equity
Current liabilities
Notes payable - current portion
-	-	-	-	-	-	-	1,396	2,697	3,962	5,194	5,066	4,958	4,853	4,750	3,878	2,643	1,434	251	1,087	158	-	-	-
Accounts payable
3,003	2,317	5,330	2,941	3,025	1,799	874	1,309	2,824	1,435	1,503	1,431	3,275	1,468	833	876	1,223	1,360	734	564	1,034	641	4,324	522
Accrued expenses and other current liabilities
3,936	4,139	4,398	4,485	3,720	1,809	2,995	2,311	2,392	1,439	2,022	1,443	1,673	815	980	1,483	3,101	2,524	2,224	1,082	-	1,645	-	-
Operating leases
178	172	167	161	156	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued collaborative expenses - related party
-	-	-	-	-	-	-	-	-	-	-	6,646	3,078	2,547	-	-	-	-	-	-	-	-	-	-
Accrued collaborative expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,533	-	-	-	-	-	-	-	-	-
Accrued expenses and other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,771	-	-	815
Accrued collaborative expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,078	1,461	1,222	-	-
Accrued expenses and other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,338	-
Convertible promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,007	58
Loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,382	-
Derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10
Total current liabilities
7,118	6,629	9,895	7,588	6,902	3,609	3,870	5,017	7,914	6,838	8,720	14,587	12,986	9,685	10,098	6,238	6,969	5,319	3,211	3,812	4,425	3,509	10,053	1,406
Deferred taxes
1,803	1,803	4,057	4,057	4,057	4,057	4,057	-	-	4,057	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
41,175	41,175	41,175	41,175	41,175	41,175	41,175	-	-	41,175	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncurrent operating leases
64	111	156	201	243	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Notes payable - noncurrent
-	-	-	-	-	-	-	-	-	-	-	1,326	2,600	3,841	5,048	6,225	7,376	8,503	9,606	8,696	9,546	-	-	-
Deferred taxes
-	-	-	-	-	-	-	4,057	4,057	-	13,433	13,433	13,433	13,433	13,433	13,433	13,433	13,433	13,433	13,433	13,433	13,433	13,668	7,588
Deferred revenue
-	-	-	-	-	-	-	41,175	41,175	-	41,175	-	-	-	-	-	-	-	-	-	-	-	-	-
Other noncurrent liabilities
-	-	-	-	-	28	30	30	30	29	-	-	-	-	-	-	-	-	-	2	5	7	-	-
Total liabilities
50,161	49,719	55,286	53,023	52,378	48,871	49,133	50,281	53,177	52,101	63,329	29,347	29,020	26,960	28,581	25,897	27,779	27,256	26,250	25,945	27,411	16,950	23,722	8,995
Commitments and contingencies (Note 8)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders’ equity
Preferred stock; $0.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of March 31, 2020 and December 31, 2019, respectively
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	-	0
Common stock; $0.0001 par value; 125,000,000 shares authorized; 39,219,134 and 39,084,121 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively
3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	2	2	2	1	0	0
Additional paid-in capital
317,507	314,511	312,341	310,120	307,800	304,813	302,739	299,986	298,088	295,975	294,717	251,311	249,785	238,836	236,587	235,632	176,463	157,129	156,438	155,810	155,257	126,228	69,367	38,008
Accumulated deficit
-298,887	-286,736	-256,818	-242,856	-230,379	-214,552	-201,349	-189,329	-176,799	-164,381	-164,543	-153,282	-143,502	-132,858	-123,454	-115,030	-109,817	-101,812	-93,373	-87,434	-80,824	-74,731	-40,133	-17,829
Total stockholders’ equity
18,624	27,779	55,527	67,268	77,424	90,264	101,393	110,661	121,293	131,597	130,177	98,032	106,286	105,982	113,137	120,605	66,649	55,319	63,067	68,377	74,435	51,499	29,234	20,179
Total liabilities and stockholders’ equity
68,785	77,498	110,813	120,291	129,803	139,136	150,526	160,943	174,471	183,698	193,507	127,379	135,306	132,942	141,718	146,502	94,428	82,576	89,318	94,323	101,847	68,450	52,956	29,174